Evolus (EOLS) Stock Forecast & Price Target

Evolus Inc. reported a 3.7% year-over-year increase in total net revenue, reaching $69.4 million, primarily driven by a rise in Jeuveau sales and the successful launch of the Evolysse dermal filler line. The company anticipates that the Evolysse product will contribute approximately 10-12% to its 2025 top-line guidance, equating to around $33 million, reflecting strong initial consumer demand. The growth potential of the aesthetic market is bolstered by younger consumers' favorable attitudes toward aesthetic treatments, which positions Evolus favorably for future market share expansion.

Evolus Inc has experienced a decline in adjusted gross margin, which fell from 71.5% to 66.5%, primarily due to an increased proportion of international sales and competitive pricing strategies aimed at boosting product adoption. The company's revised net revenue guidance for 2025 has been significantly lowered to $295-$305 million, reflecting a growth projection of only 11%-15%, compared to an earlier forecast of 30%-33%. Additionally, Jeuveau's sales in the second quarter of 2025 dropped by 11% year-over-year and 13% quarter-over-quarter, marking a troubling downturn attributed to weakened consumer sentiment and a broader decline in procedure volumes in the U.S. aesthetic market.